{"id":51086,"date":"2026-01-07T13:15:50","date_gmt":"2026-01-07T11:15:50","guid":{"rendered":"https:\/\/www.cobalt.legal\/?p=51086"},"modified":"2026-01-07T13:15:50","modified_gmt":"2026-01-07T11:15:50","slug":"sk-capital-lp-isigijo-swixx-biopharma-group","status":"publish","type":"post","link":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/","title":{"rendered":"SK Capital LP \u012fsigijo Swixx BioPharma Group"},"content":{"rendered":"<p>JAV privataus kapitalo investuotojas SK Capital LP \u012fsigijo vien\u0105 i\u0161 pasaulyje pirmaujan\u010di\u0173 biotechnologini\u0173 vaist\u0173 platinimo bendrovi\u0173 \u2013 Swixx BioPharma Group, kurios vert\u0117 po \u0161ios investicijos vir\u0161ija 1,5 mlrd. eur\u0173.<\/p>\n<p>COBALT, kartu su pagrindiniais teisiniais patar\u0117jais B\u00e4r &amp; Karrer, konsultavo SK Capital LP \u0161io sandorio klausimais, atliko vienos i\u0161 Swixx BioPharma Group Lietuvos dukterini\u0173 bendrovi\u0173 teisin\u012f patikrinim\u0105 ir u\u017etikrino atitikt\u012f Lietuvos teis\u0117s aktams.<\/p>\n<p>SK Capital Partners yra Niujorke \u012fsik\u016brusi privati investicij\u0173 bendrov\u0117, orientuota \u012f gyvyb\u0117s moksl\u0173, specializuot\u0173 med\u017eiag\u0173 ir ingredient\u0173 sektorius. Swixx BioPharma Group yra viena i\u0161 pirmaujan\u010di\u0173 pasaulio \u012fmoni\u0173, teikian\u010di\u0173 visas biovaist\u0173 platinimo paslaugas ir turinti stiprias pozicijas Vidurio ir Ryt\u0173 Europoje bei Lotyn\u0173 Amerikoje.<\/p>\n<p>\u0160iame sandoryje komandai vadovavo partneris Elijus Burgis, o projekt\u0105 koordinavo asocijuotas teisininkas Aurimas Drumstas. Komand\u0105 taip pat sudar\u0117 patar\u0117ja Sandra Sidorait\u0117, vadovaujanti teisinink\u0117 Renata Vasiliauskien\u0117, vyresnieji teisininkai Juras \u017dyman\u010dius ir Ieva Pukelien\u0117, asocijuotosios teisinink\u0117s Ieva Milkamanavi\u010di\u016bt\u0117 ir Dovil\u0117 Platakyt\u0117, bei teisinink\u0173 pad\u0117j\u0117jai Bernard Balcevi\u010d ir Vitold Dvorak.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>JAV privataus kapitalo investuotojas SK Capital LP \u012fsigijo vien\u0105 i\u0161 pasaulyje pirmaujan\u010di\u0173 biotechnologini\u0173 vaist\u0173 platinimo bendrovi\u0173 \u2013 Swixx BioPharma Group, kurios vert\u0117 po \u0161ios investicijos vir\u0161ija 1,5 mlrd. eur\u0173. COBALT, kartu su pagrindiniais teisiniais patar\u0117jais B\u00e4r &amp; Karrer, konsultavo SK..<\/p>\n","protected":false},"author":19,"featured_media":51093,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[29],"country":[92],"class_list":["post-51086","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-lt","country-lithuania-lt"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SK Capital LP \u012fsigijo Swixx BioPharma Group | COBALT<\/title>\n<meta name=\"description\" content=\"SK Capital LP \u012fsigijo Swixx BioPharma Group. News. Naujienos. Jaunumi. Uudised.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/\" \/>\n<meta property=\"og:locale\" content=\"lt_LT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SK Capital LP \u012fsigijo Swixx BioPharma Group | COBALT\" \/>\n<meta property=\"og:description\" content=\"SK Capital LP \u012fsigijo Swixx BioPharma Group. News. Naujienos. Jaunumi. Uudised.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/\" \/>\n<meta property=\"og:site_name\" content=\"COBALT\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/CobaltLegal\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-07T11:15:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2026\/01\/sk-capital-lp-deal.png\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"750\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mindaugas Gailius\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mindaugas Gailius\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\u0117\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/\"},\"author\":{\"name\":\"Mindaugas Gailius\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/person\\\/7ba0eb856a5cbe413dbd6ae5a896740a\"},\"headline\":\"SK Capital LP \u012fsigijo Swixx BioPharma Group\",\"datePublished\":\"2026-01-07T11:15:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/\"},\"wordCount\":174,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/sk-capital-lp-deal.png\",\"articleSection\":[\"Uncategorized @lt\"],\"inLanguage\":\"lt-LT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/\",\"name\":\"SK Capital LP \u012fsigijo Swixx BioPharma Group | COBALT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/sk-capital-lp-deal.png\",\"datePublished\":\"2026-01-07T11:15:50+00:00\",\"description\":\"SK Capital LP \u012fsigijo Swixx BioPharma Group. News. Naujienos. Jaunumi. Uudised.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/#breadcrumb\"},\"inLanguage\":\"lt-LT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/sk-capital-lp-deal.png\",\"contentUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/sk-capital-lp-deal.png\",\"width\":750,\"height\":750},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/news-cases\\\/sk-capital-lp-isigijo-swixx-biopharma-group\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SK Capital LP \u012fsigijo Swixx BioPharma Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#website\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/\",\"name\":\"COBALT\",\"description\":\"Top-tier law services in Estonia, Latvia and Lithuania\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"lt-LT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#organization\",\"name\":\"COBALT\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/cobalt-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.cobalt.legal\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/cobalt-logo.png\",\"width\":400,\"height\":116,\"caption\":\"COBALT\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/CobaltLegal\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/#\\\/schema\\\/person\\\/7ba0eb856a5cbe413dbd6ae5a896740a\",\"name\":\"Mindaugas Gailius\",\"url\":\"https:\\\/\\\/www.cobalt.legal\\\/lt\\\/author\\\/mindaugas\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SK Capital LP \u012fsigijo Swixx BioPharma Group | COBALT","description":"SK Capital LP \u012fsigijo Swixx BioPharma Group. News. Naujienos. Jaunumi. Uudised.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/","og_locale":"lt_LT","og_type":"article","og_title":"SK Capital LP \u012fsigijo Swixx BioPharma Group | COBALT","og_description":"SK Capital LP \u012fsigijo Swixx BioPharma Group. News. Naujienos. Jaunumi. Uudised.","og_url":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/","og_site_name":"COBALT","article_publisher":"https:\/\/www.facebook.com\/CobaltLegal\/","article_published_time":"2026-01-07T11:15:50+00:00","og_image":[{"width":750,"height":750,"url":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2026\/01\/sk-capital-lp-deal.png","type":"image\/png"}],"author":"Mindaugas Gailius","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mindaugas Gailius","Est. reading time":"1 minut\u0117"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/#article","isPartOf":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/"},"author":{"name":"Mindaugas Gailius","@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/person\/7ba0eb856a5cbe413dbd6ae5a896740a"},"headline":"SK Capital LP \u012fsigijo Swixx BioPharma Group","datePublished":"2026-01-07T11:15:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/"},"wordCount":174,"publisher":{"@id":"https:\/\/www.cobalt.legal\/lt\/#organization"},"image":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2026\/01\/sk-capital-lp-deal.png","articleSection":["Uncategorized @lt"],"inLanguage":"lt-LT"},{"@type":"WebPage","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/","url":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/","name":"SK Capital LP \u012fsigijo Swixx BioPharma Group | COBALT","isPartOf":{"@id":"https:\/\/www.cobalt.legal\/lt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/#primaryimage"},"image":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2026\/01\/sk-capital-lp-deal.png","datePublished":"2026-01-07T11:15:50+00:00","description":"SK Capital LP \u012fsigijo Swixx BioPharma Group. News. Naujienos. Jaunumi. Uudised.","breadcrumb":{"@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/#breadcrumb"},"inLanguage":"lt-LT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/"]}]},{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/#primaryimage","url":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2026\/01\/sk-capital-lp-deal.png","contentUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2026\/01\/sk-capital-lp-deal.png","width":750,"height":750},{"@type":"BreadcrumbList","@id":"https:\/\/www.cobalt.legal\/lt\/news-cases\/sk-capital-lp-isigijo-swixx-biopharma-group\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cobalt.legal\/lt\/"},{"@type":"ListItem","position":2,"name":"SK Capital LP \u012fsigijo Swixx BioPharma Group"}]},{"@type":"WebSite","@id":"https:\/\/www.cobalt.legal\/lt\/#website","url":"https:\/\/www.cobalt.legal\/lt\/","name":"COBALT","description":"Top-tier law services in Estonia, Latvia and Lithuania","publisher":{"@id":"https:\/\/www.cobalt.legal\/lt\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cobalt.legal\/lt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"lt-LT"},{"@type":"Organization","@id":"https:\/\/www.cobalt.legal\/lt\/#organization","name":"COBALT","url":"https:\/\/www.cobalt.legal\/lt\/","logo":{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/logo\/image\/","url":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/04\/cobalt-logo.png","contentUrl":"https:\/\/www.cobalt.legal\/wp-content\/uploads\/2023\/04\/cobalt-logo.png","width":400,"height":116,"caption":"COBALT"},"image":{"@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/CobaltLegal\/"]},{"@type":"Person","@id":"https:\/\/www.cobalt.legal\/lt\/#\/schema\/person\/7ba0eb856a5cbe413dbd6ae5a896740a","name":"Mindaugas Gailius","url":"https:\/\/www.cobalt.legal\/lt\/author\/mindaugas\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts\/51086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/users\/19"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/comments?post=51086"}],"version-history":[{"count":2,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts\/51086\/revisions"}],"predecessor-version":[{"id":51101,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/posts\/51086\/revisions\/51101"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/media\/51093"}],"wp:attachment":[{"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/media?parent=51086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/categories?post=51086"},{"taxonomy":"country","embeddable":true,"href":"https:\/\/www.cobalt.legal\/lt\/wp-json\/wp\/v2\/country?post=51086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}